Academic Journal
View in EDS

SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study – the BELCOMID study

Bibliographic Details
Title: SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study – the BELCOMID study
Authors: Jeroen Geldof, Marie Truyens, João Sabino, Marc Ferrante, Jo Lambert, Hilde Lapeere, Tom Hillary, An Van Laethem, Kurt de Vlam, Patrick Verschueren, Elizaveta Padalko, Triana Lobaton, Séverine Vermeire
Source: Frontiers in Immunology, Vol 14 (2023)
Publisher Information: Frontiers Media S.A., 2023.
Publication Year: 2023
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: SARS-CoV-2, COVID19, IMID, biologic, immunomodulator, real-world data, Immunologic diseases. Allergy, RC581-607
More Details: BackgroundThe risks and impact of COVID19 disease and vaccination in patients with Immune Mediated Inflammatory Diseases (IMID) remain incompletely understood. IMID patients and particularly patients receiving immunosuppressive treatment were excluded from the original, registrational phase-3 COVID19 vaccination efficacy and safety trials. Real-world observational data can help to fill this gap in knowledge. The BELCOMID study aims to explore the interaction between IMIDs, immune-modulating treatment modalities and SARS-CoV-2 infection and vaccination in a real-life patient cohort.MethodsA multidisciplinary, prospective, observational cohort study was set up. Consecutive patients with IMIDs of the gut, joints and skin followed at two high-volume referral centers were invited. Both patients under conventional treatment or targeted immune modulating therapies were included. Patient data and serological samples were collected at 3 predefined periods (before COVID19 vaccination, before booster vaccination, after booster vaccination). Primary endpoints were positive PCR-test and SARS-CoV-2 serology reflecting previous SARS-CoV-2 infection or vaccination. Associations with IMID treatment modality and IMID disease activity were assessed. Results of the first two inclusion periods (before booster vaccination) are reported.ResultsAt the first inclusion period data was assessed of 2165 IMID-patients before COVID19 vaccination. At the second inclusion period, data of 2065 patients was collected of whom 1547 had received complete baseline COVID19 vaccination and 222 were partially vaccinated. SARS-CoV-2 infection rate remained low in both groups. No significant increase in IMID flare-up rate was noted in patients with prior SARS-CoV-2 infection. Multiple logistic regression analyses did not show a significant influence of IMID-treatment modality or IMID activity on SARS-CoV-2 infection risk (based on PCR positivity or N-serology). Patients treated with conventional immunomodulators, systemic steroids, and patients on advanced therapies such as biologics or small molecules, had reduced S-antibody seroconversion. S-antibody response was also lower in patients without prior SARS-CoV-2 infection and in active smokers. A subset of patients (4.1%) had no S- nor N-antibody seroconversion following complete baseline vaccination.ConclusionThe BELCOMID study results confirm the benign course of COVID19 infection and vaccination in a large real-life IMID-population. However, our results underscore the need for repeated vaccination and smoking cessation in patients with IMIDs treated with immune-modulating therapies or systemic steroids during the pandemic.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-3224
Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1126351/full; https://doaj.org/toc/1664-3224
DOI: 10.3389/fimmu.2023.1126351
Access URL: https://doaj.org/article/99456f9e284e4ed789c888338138e551
Accession Number: edsdoj.99456f9e284e4ed789c888338138e551
Database: Directory of Open Access Journals
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=16643224&ISBN=&volume=14&issue=&date=20230301&spage=&pages=&title=Frontiers in Immunology&atitle=SARS-CoV-2%20infection%20and%20COVID19%20vaccination%20across%20eight%20immune-mediated%20inflammatory%20disorders%3A%20A%20prospective%2C%20real-life%20Belgian%20cohort%20study%20%E2%80%93%20the%20BELCOMID%20study&aulast=Jeroen%20Geldof&id=DOI:10.3389/fimmu.2023.1126351
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/99456f9e284e4ed789c888338138e551
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.99456f9e284e4ed789c888338138e551
RelevancyScore: 961
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 961.003051757813
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study – the BELCOMID study
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Jeroen+Geldof%22">Jeroen Geldof</searchLink><br /><searchLink fieldCode="AR" term="%22Marie+Truyens%22">Marie Truyens</searchLink><br /><searchLink fieldCode="AR" term="%22João+Sabino%22">João Sabino</searchLink><br /><searchLink fieldCode="AR" term="%22Marc+Ferrante%22">Marc Ferrante</searchLink><br /><searchLink fieldCode="AR" term="%22Jo+Lambert%22">Jo Lambert</searchLink><br /><searchLink fieldCode="AR" term="%22Hilde+Lapeere%22">Hilde Lapeere</searchLink><br /><searchLink fieldCode="AR" term="%22Tom+Hillary%22">Tom Hillary</searchLink><br /><searchLink fieldCode="AR" term="%22An+Van+Laethem%22">An Van Laethem</searchLink><br /><searchLink fieldCode="AR" term="%22Kurt+de+Vlam%22">Kurt de Vlam</searchLink><br /><searchLink fieldCode="AR" term="%22Patrick+Verschueren%22">Patrick Verschueren</searchLink><br /><searchLink fieldCode="AR" term="%22Elizaveta+Padalko%22">Elizaveta Padalko</searchLink><br /><searchLink fieldCode="AR" term="%22Triana+Lobaton%22">Triana Lobaton</searchLink><br /><searchLink fieldCode="AR" term="%22Séverine+Vermeire%22">Séverine Vermeire</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Frontiers in Immunology, Vol 14 (2023)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Frontiers Media S.A., 2023.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2023
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Immunologic diseases. Allergy
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22SARS-CoV-2%22">SARS-CoV-2</searchLink><br /><searchLink fieldCode="DE" term="%22COVID19%22">COVID19</searchLink><br /><searchLink fieldCode="DE" term="%22IMID%22">IMID</searchLink><br /><searchLink fieldCode="DE" term="%22biologic%22">biologic</searchLink><br /><searchLink fieldCode="DE" term="%22immunomodulator%22">immunomodulator</searchLink><br /><searchLink fieldCode="DE" term="%22real-world+data%22">real-world data</searchLink><br /><searchLink fieldCode="DE" term="%22Immunologic+diseases%2E+Allergy%22">Immunologic diseases. Allergy</searchLink><br /><searchLink fieldCode="DE" term="%22RC581-607%22">RC581-607</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: BackgroundThe risks and impact of COVID19 disease and vaccination in patients with Immune Mediated Inflammatory Diseases (IMID) remain incompletely understood. IMID patients and particularly patients receiving immunosuppressive treatment were excluded from the original, registrational phase-3 COVID19 vaccination efficacy and safety trials. Real-world observational data can help to fill this gap in knowledge. The BELCOMID study aims to explore the interaction between IMIDs, immune-modulating treatment modalities and SARS-CoV-2 infection and vaccination in a real-life patient cohort.MethodsA multidisciplinary, prospective, observational cohort study was set up. Consecutive patients with IMIDs of the gut, joints and skin followed at two high-volume referral centers were invited. Both patients under conventional treatment or targeted immune modulating therapies were included. Patient data and serological samples were collected at 3 predefined periods (before COVID19 vaccination, before booster vaccination, after booster vaccination). Primary endpoints were positive PCR-test and SARS-CoV-2 serology reflecting previous SARS-CoV-2 infection or vaccination. Associations with IMID treatment modality and IMID disease activity were assessed. Results of the first two inclusion periods (before booster vaccination) are reported.ResultsAt the first inclusion period data was assessed of 2165 IMID-patients before COVID19 vaccination. At the second inclusion period, data of 2065 patients was collected of whom 1547 had received complete baseline COVID19 vaccination and 222 were partially vaccinated. SARS-CoV-2 infection rate remained low in both groups. No significant increase in IMID flare-up rate was noted in patients with prior SARS-CoV-2 infection. Multiple logistic regression analyses did not show a significant influence of IMID-treatment modality or IMID activity on SARS-CoV-2 infection risk (based on PCR positivity or N-serology). Patients treated with conventional immunomodulators, systemic steroids, and patients on advanced therapies such as biologics or small molecules, had reduced S-antibody seroconversion. S-antibody response was also lower in patients without prior SARS-CoV-2 infection and in active smokers. A subset of patients (4.1%) had no S- nor N-antibody seroconversion following complete baseline vaccination.ConclusionThe BELCOMID study results confirm the benign course of COVID19 infection and vaccination in a large real-life IMID-population. However, our results underscore the need for repeated vaccination and smoking cessation in patients with IMIDs treated with immune-modulating therapies or systemic steroids during the pandemic.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 1664-3224
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1126351/full; https://doaj.org/toc/1664-3224
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.3389/fimmu.2023.1126351
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/99456f9e284e4ed789c888338138e551" linkWindow="_blank">https://doaj.org/article/99456f9e284e4ed789c888338138e551</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.99456f9e284e4ed789c888338138e551
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.99456f9e284e4ed789c888338138e551
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2023.1126351
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: SARS-CoV-2
        Type: general
      – SubjectFull: COVID19
        Type: general
      – SubjectFull: IMID
        Type: general
      – SubjectFull: biologic
        Type: general
      – SubjectFull: immunomodulator
        Type: general
      – SubjectFull: real-world data
        Type: general
      – SubjectFull: Immunologic diseases. Allergy
        Type: general
      – SubjectFull: RC581-607
        Type: general
    Titles:
      – TitleFull: SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study – the BELCOMID study
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jeroen Geldof
      – PersonEntity:
          Name:
            NameFull: Marie Truyens
      – PersonEntity:
          Name:
            NameFull: João Sabino
      – PersonEntity:
          Name:
            NameFull: Marc Ferrante
      – PersonEntity:
          Name:
            NameFull: Jo Lambert
      – PersonEntity:
          Name:
            NameFull: Hilde Lapeere
      – PersonEntity:
          Name:
            NameFull: Tom Hillary
      – PersonEntity:
          Name:
            NameFull: An Van Laethem
      – PersonEntity:
          Name:
            NameFull: Kurt de Vlam
      – PersonEntity:
          Name:
            NameFull: Patrick Verschueren
      – PersonEntity:
          Name:
            NameFull: Elizaveta Padalko
      – PersonEntity:
          Name:
            NameFull: Triana Lobaton
      – PersonEntity:
          Name:
            NameFull: Séverine Vermeire
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 16643224
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in Immunology
              Type: main
ResultId 1